Algert Global LLC Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Algert Global LLC reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 64.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,951 shares of the specialty pharmaceutical company's stock after selling 23,629 shares during the quarter. Algert Global LLC owned approximately 0.06% of ANI Pharmaceuticals worth $825,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ANIP. Innealta Capital LLC purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth about $65,000. Ridgewood Investments LLC bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $85,000. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $106,000. ADAR1 Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $132,000. Finally, Clear Street Markets LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter worth about $140,000. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the sale, the chief operating officer now owns 635,363 shares in the company, valued at $40,129,527.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 26,007 shares of company stock worth $1,642,990. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Trading Up 1.8 %

ANIP traded up $1.04 during midday trading on Friday, reaching $57.83. 74,438 shares of the company's stock traded hands, compared to its average volume of 213,426. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of 36.14 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The firm has a fifty day moving average of $60.16 and a two-hundred day moving average of $63.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period in the previous year, the company posted $1.06 earnings per share. The firm's revenue was up 18.5% on a year-over-year basis. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Truist Financial reiterated a "hold" rating and issued a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. Finally, HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $78.80.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.